Tests for Chronic Obstructive Pulmonary Disease (COPD)

  1. ๐Ÿ“š Citations
  2. ๐Ÿฆ  Taxons (Bacteria) report by studies
  3. ๐Ÿฅฃ Candidates for improving (avoids and takes)
  4. ๐Ÿ”ฎ Bacteria Related Conditions
  5. es-xenogene is located in Spain and is expensive compared to others

Some 16s providers support download of FASTQ (raw data - BIG FILES). These can be processed thru other services (at the moment, Thryve and Biomesight offers free processing). The bacteria is determine by computer algorithms, which differs from lab to lab.

  1. Biomesight and BiomeSightRdp ships worldwide - including the US
  2. Thryve is now Ombre Labs but only ships to the US
  3. CosmosId is available thru NirvanaBiome
  4. Medivere is based in Germany
  5. American Gut
  6. Xenogene is both the most expensive and most detail for rare bacteria. They are based in Spain
  7. uBiome is no longer in business
The Percentage of significant bacteria each test reports on
Name Percentage
es-xenogene 96.7%
Thryve 96.7%
FASTQ processed thru both Thryve and BiomeSight 96.7%
Thorne 90%
Tiny 86.7%
BiomeSightRdp 83.3%
CerbaLab 83.3%
CosmosId 83.3%
Medivere 80%
uBiome 80%
SequentiaBiotech 80%
bugspeak 76.7%
BiomeSight 73.3%
AmericanGut 66.7%
Microba 56.7%
GanzimmunDiag 43.3%
Microba1 33.3%
Metagenomics Stool (De Meirleir) (16s Limited) 26.7%
Gut Zoomer (vibrant-wellness) 26.7%
Biovis Microbiome Plus (cfu/g) 23.3%
Viome (Latest Reports Fail to provide ANY measurements) 20%
Medivere Mikrobiom Plus Stuhlanalyse 16.7%
DayTwo 16.7%
Diagnostic Solution GI-Map (cfu/gm) 16.7%
GanzImmun Diagnostic A6 (cfu/gm) 16.7%
Genova Gi Effects (cfu/g) 16.7%
GI360 Stool (UK) 16.7%
Bioscreen (cfu/gm) 13.3%
Smart Gut (ubiome 16s - Limited Taxonomy) 13.3%
Nordic Laboratories 10%
NutriPATH 6.7%
Medivere: Darm Mikrobiom Stuhltest (16s limited) 6.7%
InVitaLab (cfu/gm) 6.7%
Genova Parasitology (cfu/g) 3.3%
GI EcologiX (Invivo) 3.3%

All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.

Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 ยงโ€ฏ1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.

The awesome web hosting site that we use. Try it if you need to host (or unhappy with current provider)